Application of Gene Editing Technology Based on Targeted Delivery Materials in TNBC.

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options due to heterogeneity and drug resistance.
• Current targeted therapies face challenges in TNBC treatment efficacy.
• Gene editing technologies present novel therapeutic strategies for TNBC.

Purpose of the Study:

• To review key regulatory genes in TNBC progression.
• To discuss advancements in gene editing tools and delivery systems for TNBC.
• To address challenges and propose solutions for clinical translation of gene editing in TNBC.

Main Methods:

• Systematic review of literature on TNBC regulatory genes.
• Analysis of gene editing technologies (CRISPR/Cas9, RNA interference).
• Evaluation of targeted delivery materials (viral and nonviral vectors).

Main Results:

• Identified key genes (BRCA1/2, TP53, MUC1, EGFR, MYC) regulating TNBC progression.
• Highlighted progress in gene editing tools and delivery systems for enhanced specificity and reduced immune response.
• Discussed biosafety, ethical concerns, and mitigation strategies for gene editing in TNBC.

Conclusions:

• Gene editing holds significant promise for developing targeted and personalized TNBC therapies.
• Overcoming delivery, off-target effects, and safety concerns is crucial for clinical application.
• Further research integrating gene editing with advanced delivery systems can improve TNBC treatment outcomes.